VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-03

Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-08	Common Stock	G	3391	$0.00	Disposed	7368	Indirect
2021-02-03	Common Stock	A	10126	$0.00	Acquired	48472	Direct
2021-02-03	Common Stock	A	10324	$0.00	Acquired	58796	Direct
2021-02-03	Common Stock	A	11627	$0.00	Acquired	70423	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	882	Indirect

Footnotes

F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.

F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021.

F3: Restricted stock unit award that vests in installments beginning on 02/17/2022.